The Duke treadmill scoring (DTS) system confers better risk stratification and provides more substantial information about the different classification of risks in patients suspected of coronary artery disease (CAD) compared with conventional treadmill reading, according to a study presented at the Asian Pacific Society of Cardiology (APSC) 2019 Congress held at the SMX Convention Center in Manila, Philippines.
Beta blockers (BB) and renin-angiotensin inhibitors (RAI) effectively protect against anthracycline-induced cardiotoxicity among cancer patients, preserving left ventricular ejection fraction (LVEF) and cutting cardiac events, according to a new study presented at the recently concluded 2019 Congress of the Asian Pacific Society of Cardiology (APSC).
New York Heart Association (NYHA) functional class III, multiple valve involvement and right ventricular area change predict the incidence of adverse outcomes among medically treated patients with valvular heart disease (VHD), according to a new study presented at the Asian Pacific Society of Cardiology (APSC) 2019 Congress held at the SMX Convention Center in Manila, Philippines.
Among patients with dilated cardiomyopathy (DCM), a history of methamphetamine use does not amplify the risk of death or of nonfatal outcomes, such as myocardial infarction, stroke or heart failure, according to a study presented at the recently concluded 2019 Congress of the Asian Pacific Society of Cardiology (APSC 2019).
Among patients chronically infected with hepatitis C virus (HCV), presenting with elevated blood pressure during initiation of antiviral therapy is associated with treatment failure, according to a study presented at the Asian Pacific Society of Cardiology (APSC) Congress 2019.
Use of an intermittent pneumatic compression device as an adjunct treatment helps improve quality of life and walking endurance in patients with lower extremity arterial disease, as shown in the results of a pilot study presented at the Asian Pacific Society of Cardiology (APSC) Congress 2019.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Cardiology - Malaysia digital copy today!
The efficacy and cardiovascular (CV) safety of the SGLT2* inhibitor empagliflozin vs DPP-4** inhibitors and GLP-1*** receptor agonists in real-world patients were demonstrated in two interim analyses of the EMPRISE+ study presented at ADA 2020.
Patients hospitalized with mild-to-moderate COVID-19 who are on angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for hypertension should continue these medications, according to primary results of the BRACE CORONA trial presented at ESC 2020.
Targeting a low-density lipoprotein cholesterol level <70 mg/dL following an ischaemic stroke of atherosclerotic origin helps to avoid one in four subsequent major vascular events without increasing the risk of intracranial haemorrhage over about 5 years of follow-up, according to data from the Treat Stroke to Target trial.